Elicio Therapeutics, Inc. Share Price & Technical Analysis
ELTX · $9.95 (+0.51%)
Healthcare / Biotechnology
$9.95
+0.51%
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targe…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
-7% return in May, 17% avg return in past 3 year May month.
40% return in 2026, 42% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -6% | 71% | -18% | -1% | -7% | – | – | – | – | – | – | – | 40% |
| 25 | 86% | -10% | -26% | -21% | 44% | 7% | 26% | 7% | 4% | -15% | -1% | -15% | 86% |
| 24 | -46% | -7% | 90% | 35% | -14% | -48% | 21% | -24% | 25% | -16% | 16% | -2% | 30% |
| 23 | -11% | -9% | -9% | 36% | 23% | -10% | 0% | -16% | -1% | -19% | -9% | 36% | 9% |
| 22 | -8% | -31% | 7% | -42% | 41% | -37% | 2% | -5% | -9% | 11% | -17% | -5% | -94% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$199.39M
P/E ratio
—
52W high
$14.93
52W low
$5.80
Volume
1,10,377
Beta
1.45
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Elicio Therapeutics, Inc. share price today?
- Elicio Therapeutics, Inc. (ELTX) last traded around $9.95 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ELTX have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ELTX. Download the app for real-time alerts.
- How can I analyze Elicio Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.